The first patient, a 64-year-old man from Italy, spent 1 week (April 25–May 1, 2010) in a touristic village in southern Egypt, near the Sudan border. While visiting a camel and dromedary market in Shalatin on April 29, he was bitten on the foot by an unidentified arthropod (although not formally identified, was described as tick shaped). Soon after, a small, papular lesion developed. During his return flight to Italy, ≈48 hours after the bite, the patient experienced high fever, shaking chills, anorexia, malaise, nausea and vomiting, and blurred vision. During the next 5 days, these signs and symptoms worsened, and the man was admitted to the “Ospedali Riuniti di Bergamo” in northern Italy. His medical history was unremarkable, but he frequently traveled abroad and had been vaccinated against yellow fever in 1998.

Laboratory test results showed leukopenia (2,250 cells/mm³), thrombocytopenia (67,000 platelets/mm³), and increased liver enzymes (aspartate transaminase 469 U/L, reference 3–46 U/L; alanine transaminase 406 U/L, reference 3–46 U/L). The patient was given acetaminophen, and fever and general malaise progressively decreased over the next 5 days. He was discharged 11 days later, on May 17, in good general condition despite persistence of asthenia.

Acute-phase and convalescent-phase serum samples (collected on May 10 and 27, respectively) were sent to the virology laboratory of the “Lazzaro Spallanzani” National Institute for Infectious Diseases in Rome to be tested for dengue and West Nile viruses. Immunoglobulins (Ig) G and M for both viruses were detected by immunofluorescence of both samples; for each virus, IgG titer was >640 and IgM titer was >20. No evidence of rising antibody titers was found in the convalescent-phase specimen, raising suspicion of cross-reactivity to a previous Flavivirus infection or yellow fever vaccination. A genus-specific reverse transcription–PCR selective for the nonstructural protein (NS) 5 gene of flaviviruses (11) was positive for the acute-phase and negative for the convalescent-phase samples. Sequence analysis of the amplicon (GenBank accession no. HM629507) showed high similarity with ALKV sequences in GenBank (BLAST [www.ncbi.nlm.nih.gov/blast/Blast.cgi] submission showed 97% identity with AF331718). This unexpected result called for further investigations to confirm the diagnosis of an ALKV infection. Thus, an ALKV-specific nested reverse transcription–PCR selective for a wider region of a different gene (E) was designed by using the following primers: outer forward 5′-TGGAACCCCACACGGGTGACT-3′; outer reverse 5′-ATGCCCACTGTCGGTTGGCG-3′; inner forward 5′-CCCACAGCAATCGAAAAACGGCATC-3′; inner reverse 5′- GCCCACATCACAGGTGACATGACC-3′.

All residual biological samples collected during the patient’s hospital stay were sent to the virology laboratory of the Spallanzani Hospital (Italy’s national reference laboratory for viral hemorrhagic fever viruses, BioSafety Level 4) in compliance with biosafety procedures. The new ALKV PCR result was positive, and the sequence of the amplicon (GenBank accession no. HM629508) showed high homology with ALKV (99% identity with AF331718). The phylogenetic trees based on partial sequences of NS5 (Figure 1) and E (Figure 2) genes confirmed the diagnosis of ALKV infection.

After submitting this article, we detected ALKV infection in a second patient. This patient had traveled to the same area ≈1 month later, visited the same camel market, and was affected by a milder disease. NS5 (HQ218942) and E (HQ218941) gene sequences obtained from this patient have been included in the phylogenetic tree, showing that they cluster together with those from the first patient (Figure 1, Figure 2).

The 2 patients had traveled to an area of the world where ALKV had not been previously reported. Although viremia was demonstrated 10 days after symptom onset, and we can reliably suppose that it started when fever and chills appeared, the probability of a susceptible vector in Europe is small, and the infection seems not to be transmissible from human to human.

Laboratory diagnosis of this infection is not easy to obtain and requires a specialized laboratory because of antibody cross-reactivity with other members of the family Flaviviridae and because of the absence of commercially available serologic tests and reference biologic materials for their development. However, surveillance of travelers returning from areas where highly dangerous infectious diseases are endemic should be improved and should include ALKV. The finding that the distribution of this virus is wider than previously thought and that it includes the African continent is in line with the hypothesis that tick-borne flaviviruses originated in Africa (12). The low genetic distance between the Egypt and Saudi Arabia sequences supports the hypothesis of a recent divergence from Kyasanur Forest disease virus, i.e., the closest flavivirus (5), and a slow microevolution of ALKV, as for other tick-borne flaviviruses (13). The higher genetic divergence in the NS5 gene than in the E gene of ALKV strains confirms previous observations for viruses isolated from human samples after inoculation of suckling mice (5) and deserves more detailed evolutionary analysis.

The detection of 2 independent infection events for travelers who visited the same area in a restricted period strongly supports the hypothesis of sustained local ALKV circulation. Further veterinary and entomologic investigations are needed to expand understanding of the geographic distribution of ALKV and to assess the danger for local populations and visitors. It would be advisable to inform travelers about the danger of coming into contact with infected animals in areas where the virus has been reported. Avoidance of or minimization of exposure to infected ticks should be recommended as the most effective prevention measure.